Evidence map›Paper›PMID 35708871›Full record

ArticleCVIR endovascular2022

Long-term efficacy and risk factors for stent occlusion in portal vein stent placement: a multi-institutional retrospective study.

Hirotsugu Nakai, Hironori Shimizu, Takanori Taniguchi, Seiya Kawahara, Toshihide Yamaoka, Naoya Sasaki, Hiroyoshi Isoda, Yuji Nakamoto

Open access · goldAbstract read
In one paragraph

Article in CVIR endovascular, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Portal vein stent to save the day.CVIR endovascular · 2025
    Article
  3. Article
  4. Article
  5. A Case of Superior Mesenteric Artery Occlusion Caused by Portal Vein Stenting.Interventional radiology (Higashimatsuyama-shi (Japan) · 2025
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Hirotsugu NakaiDepartment of Radiology, Tenri Hospital, 200 Mishima-cho, Tenri, Nara, 632-8552, Japan. nakai.hirotsugu.m37@kyoto-u.jp.ORCID http://orcid.org/0000-0002-2080-5901
Hironori ShimizuDepartment of Diagnostic Imaging and Nuclear Medicine, Kyoto University Graduate School of Medicine, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan.
Takanori TaniguchiDepartment of Radiology, Tenri Hospital, 200 Mishima-cho, Tenri, Nara, 632-8552, Japan.
Seiya KawaharaDepartment of Radiology, Otsu Red Cross Hospital, Nagara 1-1-35, Otsu, Shiga, 520-0046, Japan.
Toshihide YamaokaDepartment of Diagnostic Imaging and Interventional Radiology, Kyoto Katsura Hospital, 17 Yamada-Hirao, Nishikyo, Kyoto, 615-8256, Japan.
Naoya SasakiDepartment of Surgery, Kyoto Katsura Hospital, 17 Yamada-Hirao, Nishikyo, Kyoto, 615-8256, Japan.
Hiroyoshi IsodaDepartment of Diagnostic Imaging and Nuclear Medicine, Kyoto University Graduate School of Medicine, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan.
Yuji NakamotoDepartment of Diagnostic Imaging and Nuclear Medicine, Kyoto University Graduate School of Medicine, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan.
Kyoto University · JPKyoto Katsura Hospital · JPOtsu Red Cross Hospital · JPTenri Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSurgical treatment for PV (portal vein) stenosis/occlusion can pose a fatal risk of massive bleeding from severe adhesions and collateral vessel formation. PV stents placement is a minimally invasive and effective procedure for PV stenosis/occlusion, but PV stents sometimes occlude. The relationship between post-stent PV hemodynamics and stent occlusion has not been thoroughly investigated. Certain precautions during PV stent placement may reduce the risk of stent occlusion. This study aimed to evaluate long-term outcomes of PV stent patency and investigate factors including PV hemodynamics associated with stent occlusion. MATERIALS AND

methodsThirty-four consecutive patients with PV stenosis/occlusion who underwent PV stent placement in four institutions between December 2006 and February 2021 were retrospectively examined. The primary study endpoints were technical success, clinical success, and cumulative stent patency rate. The secondary endpoints were risk factors of stent occlusion. A univariable Cox proportional hazards model with sixteen variables was used to determine predictors of stent occlusion. Factors with p-value ≤ 0.1 in univariable analysis were included in the multivariable analysis. Alpha was set at 0.05.

resultsTechnical and clinical success rates were 88.2% and 79.4%, respectively. Six patients (17.7%) experienced stent occlusion. The cumulative stent patency rate at six months, one year, and three years was 79.1%, 79.1%, and 65.9%, respectively. In the univariate analysis, the variables with p-value ≤ 0.1 were lesion length > 4 cm, hepatofugal collateral vein visualization after stent placement, and residual stenosis > 30% after stent placement. In the multivariate analysis, residual stenosis > 30% after stent placement was significantly associated with stent occlusion (hazard ratio, 10.80; 95% confidence interval, 1.08-108.44; p = 0.04).

conclusionPV stent placement was technically feasible and effective in improving portal hypertension. However, stent occlusion was not uncommon. Residual stenosis > 30% after stent placement was significantly associated with stent occlusion. We should pay attention to correctly assess the range of stenosis and release the stenosis as much as possible.

Indexed as

AscitesGastrointestinal hemorrhageHypertensionPortalPortal veinStents

Identifiers

PMID35708871
PMCPMC9203607
OpenAlexW4282962574

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.